In sharp contrast, the SBU-CD55 × CD20 antibody exhibited a remarkably increased CDC of 83% and 50.49% in Ramos-RR and BJAB, respectively (Fig. 4e,f), indicating its superior tumor cell killing efficacy in resistant tumor cell lines. Here, CD55 is linked to neoplasm.